Outer Bio Emerges With Roughly $23M for Living-Skin AI

Outer Bio emerged from stealth in August 2026 with roughly $23M raised to date and a platform built around an awkward truth for AI-driven biology: software can rank a compound quickly, but living tissue still needs time to show what that compound actually does. Wing Venture Capital announced a lead investment, although neither Wing nor Outer Bio disclosed the amount or formal series of that financing.

The distinction matters because the headline total is cumulative, not evidence of one new $23M round. Outer Bio's investor roster includes Wing, Initialized Capital, Sozo Ventures, Hawktail, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures, and SV Angel, while the company has left valuation, round chronology, and the latest check size private.

The capital is attached to Yuna, an ex vivo human-skin platform that keeps full-thickness tissue alive and measurable for four weeks. Outer Bio combines that tissue system with automated experiments, longitudinal multi-omic measurements, and machine-learning models trained on its own data, creating a loop in which software proposes, living biology tests, and every result shapes the next prediction.

What Outer Bio Disclosed About Its Funding

TechCrunch reported on August 21, 2026 that Outer Bio had raised roughly $23M to date. The report identifies Wing Ventures, Initialized Capital, and Hawktail among its early backers, while Outer Bio's August 24 press release names the broader investor group.

Wing calls its participation a lead investment but does not name the round, its size, or a valuation. That evidence supports a Funding Announcement classification with an undisclosed round type; it does not support calling the event a $23M Series A or assigning the cumulative total to Wing's latest check.

The company was co-founded by Michael Polansky, Kyung-Jin (KJ) Jang, Chris Hinojosa, and Stanley King II. Outer Bio's leadership page identifies Polansky as CEO, Jang as CSO, Hinojosa as CTO, and King as CBO, with Polansky, Stefani Germanotta, and Wing partner Sara Choi serving on the board.

How Yuna Turns Living Skin Into Training Data

Standard ex vivo skin remains useful for only a few days to roughly one week, a window that can capture acute toxicity but miss slower processes such as collagen remodeling, chronic inflammation, barrier repair, and cellular senescence. Yuna extends that experimental window to four weeks while maintaining the epidermis, dermis, multiple resident cell types, and immune-associated signaling.

The tissue rests on a proprietary porous, 3D-printed support structure that moves nutrients in and metabolic waste out at an air-liquid interface. Outer Bio also sources tissue across ages, sexes, and Fitzpatrick skin types I through VI, then tracks changes through transcriptomic, histological, secretory, and clinical-style measurements.

Outer Bio says the platform has generated more than 10TB of proprietary data across more than 300 donors and 10,000 treatments. Each compound-sample pair produces more than 30,000 data points, and the company's virtual screening library spans 5.9M compounds across 11 databases. Those are company-reported operating metrics, not independently audited commercial results.

The machine-learning layer ranks compounds before physical testing. Yuna then tests those predictions in living human tissue, including the misses, and returns the evidence to later model runs. That makes the experimental system the scarce asset: the model can improve only as fast as Outer Bio can produce reliable, diverse, longitudinal biological data.

What the Public Validation Shows and Does Not Show

Outer Bio's public materials summarize three validation settings from its 2026 bioRxiv preprint. The company reports that Yuna sustained a psoriasis-like inflammatory state that a known JAK inhibitor reduced, captured senescence-related signatures in aged donor tissue that responded to dasatinib plus quercetin, and modeled UVB injury that topical sunscreen mitigated.

These tests are useful because the interventions have known directional effects, giving the platform a way to demonstrate that it can recover expected biological answers over time. They are validation experiments, not proof that every model-ranked compound will become a safe, manufacturable, commercially successful ingredient.

Outer Bio also states the current platform's limits. Yuna preserves resident immune signaling but does not recruit circulating immune cells, and it lacks full vascular perfusion. Those boundaries matter in drug development, where systemic biology and flow-dependent processes can decide whether a promising tissue result translates beyond the platform.

Why the Business Model Depends on More Than AI

Outer Bio is not building a consumer skincare brand. The company generates revenue through research collaborations and plans to license or sell finished ingredients to beauty and pharma companies, which would handle formulation, manufacturing, safety work, and commercialization.

That approach gives Outer Bio two possible products. One is access to a human-relevant research platform for partners trying to evaluate efficacy, toxicity, or mechanism. The other is a portfolio of bioactive ingredients discovered through the same system and sold or licensed into products developed by someone else.

The combination creates a demanding handoff. A prediction has to survive living-tissue testing, then move through formulation, standardized naming, safety protocols, manufacturing scale-up, and customer adoption. The model may narrow the search, but a partner still has to put the resulting ingredient into something that can be made, sold, and trusted.

What the $23M Must Help Outer Bio Prove

Outer Bio has not published a specific use-of-proceeds schedule for the disclosed funding total. Its public roadmap includes greater experimental throughput, deeper sensor integration, advanced biology such as glands and hair, a broader validated exposure library, tighter feedback between Yuna and its prediction models, and more product-development capability.

Those priorities point toward the operating burden in front of the company. More donors and more experiments can make the dataset harder to copy, but only if results remain consistent across tissue sources, time, and partner programs. More candidates can widen the portfolio, but only if Outer Bio can move the strongest ones through the manual work that begins after discovery.

The funding total draws attention because capital is easy to compare. Outer Bio's harder asset is time under observation: four weeks of living human skin, repeated across donors, teaching software where it was right and where it failed. The next proof is whether that loop can produce repeatable partner value and ingredients that survive the trip from a model's ranking to a product on real skin.